Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 620.86 -3.09% -19.77
REGN closed down 3.09 percent on Friday, July 10, 2020, on 64 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical REGN trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
New 52 Week High Strength -3.09%
Upper Bollinger Band Walk Strength -3.09%
Outside Day Range Expansion -3.09%
Upper Bollinger Band Touch Strength -3.09%
Upper Bollinger Band Walk Strength -3.04%
Inside Day Range Contraction -3.04%
Upper Bollinger Band Touch Strength -3.04%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Biotechnology Biopharmaceutical Health Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Atopic Dermatitis Macular Edema Sanofi Breakthrough Therapy Metastatic Colorectal Cancer Allergic Asthma Immune Diseases Regeneron

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 655.9255
52 Week Low 271.37
Average Volume 1,445,239
200-Day Moving Average 441.90
50-Day Moving Average 591.70
20-Day Moving Average 617.30
10-Day Moving Average 624.75
Average True Range 22.51
ADX 18.38
+DI 21.69
-DI 14.85
Chandelier Exit (Long, 3 ATRs ) 588.38
Chandelier Exit (Short, 3 ATRs ) 643.43
Upper Bollinger Band 651.41
Lower Bollinger Band 583.18
Percent B (%b) 0.55
BandWidth 11.05
MACD Line 11.95
MACD Signal Line 12.29
MACD Histogram -0.3365
Fundamentals Value
Market Cap 65.83 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 62.27
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 653.92
Resistance 3 (R3) 656.62 648.31 648.41
Resistance 2 (R2) 648.31 639.89 646.96 646.57
Resistance 1 (R1) 634.58 634.69 630.43 631.88 644.74
Pivot Point 626.27 626.27 624.19 624.92 626.27
Support 1 (S1) 612.54 617.85 608.39 609.84 596.98
Support 2 (S2) 604.23 612.65 602.88 595.15
Support 3 (S3) 590.50 604.23 593.31
Support 4 (S4) 587.80